Evidence map›Paper›PMID 34507111›Full record

ArticleLung cancer (Amsterdam, Netherlands)2021

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.

Nanruoyi Zhou, Maria A Velez, Benjamin Bachrach, Jaklin Gukasyan, Charlene M Fares, Amy L Cummings, Jackson P Lind-Lebuffe, Wisdom O Akingbemi, Debory Y Li, Paige M Brodrick and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Nanruoyi ZhouDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Maria A VelezDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Benjamin BachrachDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Jaklin GukasyanDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Charlene M FaresDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Amy L CummingsDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Jackson P Lind-LebuffeDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Wisdom O AkingbemiDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Debory Y LiDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Paige M BrodrickDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Nawal M YessufDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Sarah RettingerDepartment of Endocrinology, Providence Health & Services, Santa Monica, CA, USA.
Tristan GroganDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Philippe RochigneuxDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Jonathan W GoldmanDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Edward B GaronDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Aaron LisbergDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: alisberg@mednet.ucla.edu.
University of California, Los Angeles · USProvidence Health & Services · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
A model for predicting response to PD-1 inhibitors in NSCLCR01CA208403 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2017 to 2021
$3.2M
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLCK08CA245249 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LISBERG, AARON ELLIOTT · 2020 to 2024
$1.3M
NCATS NIH HHS UL1 TR001881NCI NIH HHS K08 CA245249NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA208403
6 · The paper itself

Abstract

introductionThyroid dysfunction is the most frequent endocrine immune related adverse event (irAE) in non-small cell lung cancer (NSCLC), typically arising 3-6 months into immune checkpoint inhibitor (ICI) therapy, but arising after ICI cessation, in some cases. Due to limited post-treatment adverse event reporting requirements on ICI trials, the incidence of ICI-induced thyroid dysfunction arising after therapy is unclear. We investigated ICI-induced thyroid dysfunction in a cohort of 294 NSCLC patients, with a specific focus on the post-treatment setting.

methodsRetrospective analysis of ICI-induced thyroid dysfunction (clinically acted upon or laboratory only) was performed in 294 UCLA NSCLC patients treated 2012-2018. Clinically acted upon thyroid dysfunction was defined as thyroid diagnosis documentation and/or thyroid medication administration. Laboratory only dysfunction was defined as abnormal thyroid labs in the absence of clinical action. Timing of thyroid dysfunction relative to ICI treatment and thyroid monitoring patterns were also assessed.

results82% (241/294) of ICI treated NSCLC patients had thyroid labs during treatment. Of these 241 patients, 13% (31/241) had clinically acted upon thyroid dysfunction prior to, 8% (18/241) during, and 4% (9/241) after ICI. Most patients, 66% (159/241), did not have thyroid labs after ICI, but in the 53 patients with labs and no prior clinical dysfunction, 17% (9/53) developed clinical dysfunction after ICI. In these 9 patients, median time from ICI initiation to dysfunction was 253 days. Two patients with post-treatment laboratory only dysfunction were observed.

conclusionsICI-induced thyroid dysfunction arising post-treatment appears more common than previously appreciated, warranting additional evaluation.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmune Checkpoint InhibitorsRetrospective StudiesThyroid GlandImmune Checkpoint InhibitorsAnti-PD-(L)1 therapyImmune checkpoint inhibitor (ICI)Immune related adverse events (irAE)Non-small cell lung cancer (NSCLC)Thyroid dysfunction

Identifiers

PMID34507111
PMCPMC8923054
OpenAlexW3198148521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.